Ginkgo Bioworks Holdings, Inc. Logo

Ginkgo Bioworks Holdings, Inc.

A cell programming platform offering R&D services for pharma, agriculture, food, and chemicals.

DNA | US

Overview

Corporate Details

ISIN(s):
KYG8354H1267 (+2 more)
LEI:
Country:
United States of America
Address:
27 DRYDOCK AVENUE, 2210 BOSTON
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Ginkgo Bioworks Holdings, Inc. is a synthetic biology company that operates a leading horizontal platform for cell programming. Its core mission is to make biology easier to engineer, enabling customers to program cells with the ease of programming computers. The company's platform leverages high-throughput automation, proprietary software, artificial intelligence, and an extensive biological codebase to design, build, and test custom organisms for its partners. Ginkgo provides flexible, end-to-end R&D services to solve challenges across diverse markets, including pharmaceuticals, agriculture, food and nutrition, and specialty chemicals, facilitating the development of novel and more sustainable products.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Ginkgo Bioworks Holdings, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Ginkgo Bioworks Holdings, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Ginkgo Bioworks Holdings, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Alpha Tau Medical Ltd. Logo
Developing Alpha DaRT, a precision alpha-radiation therapy designed to destroy solid tumors.
United States of America
DRTS
Alteogen Inc. Logo
Biotech firm developing next-gen ADCs and biobetters with proprietary platform technologies.
South Korea
196170
AlzeCure Pharma Logo
Develops small-molecule drug therapies for Alzheimer's, pain, and cognitive dysfunction.
Sweden
ALZCUR
ANAPTYSBIO, INC Logo
Clinical-stage biotech developing immunology therapies for autoimmune and inflammatory diseases.
United States of America
ANAB
AngioLab, Inc. Logo
Develops anti-angiogenic therapeutics and foods for angiogenesis-related diseases.
South Korea
251280
Anixa Biosciences Inc Logo
Clinical-stage biotech developing CAR-T immunotherapies and vaccines to fight cancer.
United States of America
ANIX
Annovis Bio, Inc. Logo
Developing oral therapies for neurodegenerative diseases like Alzheimer's and Parkinson's.
United States of America
ANVS
Develops DNA tech for genetic medicine, molecular diagnostics, and supply chain security.
United States of America
APDN
Aprea Therapeutics, Inc. Logo
Developing precision cancer therapies targeting DNA Damage Response for solid tumors.
United States of America
APRE
AprilBio Co.,Ltd. Logo
Develops long-acting biologic drugs for autoimmune diseases and oncology using its SAFA™ platform.
South Korea
397030

Talk to a Data Expert

Have a question? We'll get back to you promptly.